I found the field of Pharmacology & Pharmacy; Chemistry very interesting. Saw the article An anthrone-based Kv7.2/7.3 channel blocker with improved properties for the investigation of psychiatric and neurodegenerative disorders published in 2019. Safety of Anthrone, Reprint Addresses Dockendorff, C (corresponding author), Marquette Univ, Dept Chem, POB 1881, Milwaukee, WI 53201 USA.. The CAS is 90-44-8. Through research, I have a further understanding and discovery of Anthrone
A set of novel Kv7.2/7.3 (KCNQ2/3) channel blockers was synthesized to address several liabilities of the known compounds XE991 (metabolic instability and CYP inhibition) and the clinical compound DMP 543 (acid instability, insolubility, and lipophilicity). Using the anthrone scaffold of the prior channel blockers, alternative heteroarylmethyl substituents were installed via enolate alkylation reactions. Incorporation of a pyridazine and a fluorinated pyridine gave an analog (compound 18, JDP-107) with a promising combination of potency (IC50=0.16 mu M in a Kv7.2 thallium flux assay), efficacy in a Kv7.2/7.3 patch clamp assay, and drug-like properties.
Welcome to talk about 90-44-8, If you have any questions, you can contact Porter, JD; Vivas, O; Weaver, CD; Alsafran, A; DiMilo, E; Arnold, LA; Dickson, EJ; Dockendorff, C or send Email.. Safety of Anthrone
Reference:
Thiomorpholine – Wikipedia,
,Thiomorpholine | C4H9NS – PubChem